Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients：An Open-label, Single-arm, Multicenter Phase I/II Study

NCT05426811 is registered in ClinicalTrials.gov with China Medical University, China as lead sponsor.

NCT NCT05426811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05426811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients：An Open-label, Single-arm, Multicenter Phase I/II Study
Lead sponsor
China Medical University, China
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 1, 2022
Completion date
December 30, 2025
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms, raltitrexed, regorafenib, third-line treatment